812 related articles for article (PubMed ID: 29330207)
1. Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.
Goldberg SB; Narayan A; Kole AJ; Decker RH; Teysir J; Carriero NJ; Lee A; Nemati R; Nath SK; Mane SM; Deng Y; Sukumar N; Zelterman D; Boffa DJ; Politi K; Gettinger SN; Wilson LD; Herbst RS; Patel AA
Clin Cancer Res; 2018 Apr; 24(8):1872-1880. PubMed ID: 29330207
[No Abstract] [Full Text] [Related]
2. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
[TBL] [Abstract][Full Text] [Related]
3. Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab.
Raja R; Kuziora M; Brohawn PZ; Higgs BW; Gupta A; Dennis PA; Ranade K
Clin Cancer Res; 2018 Dec; 24(24):6212-6222. PubMed ID: 30093454
[TBL] [Abstract][Full Text] [Related]
4. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
[TBL] [Abstract][Full Text] [Related]
5. Serial ultra-deep sequencing of circulating tumor DNA reveals the clonal evolution in non-small cell lung cancer patients treated with anti-PD1 immunotherapy.
Li L; Wang Y; Shi W; Zhu M; Liu Z; Luo N; Zeng Y; He Y
Cancer Med; 2019 Dec; 8(18):7669-7678. PubMed ID: 31692284
[TBL] [Abstract][Full Text] [Related]
6. Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies.
Lee JH; Long GV; Menzies AM; Lo S; Guminski A; Whitbourne K; Peranec M; Scolyer R; Kefford RF; Rizos H; Carlino MS
JAMA Oncol; 2018 May; 4(5):717-721. PubMed ID: 29423503
[TBL] [Abstract][Full Text] [Related]
7. Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.
Anagnostou V; Forde PM; White JR; Niknafs N; Hruban C; Naidoo J; Marrone K; Sivakumar IKA; Bruhm DC; Rosner S; Phallen J; Leal A; Adleff V; Smith KN; Cottrell TR; Rhymee L; Palsgrove DN; Hann CL; Levy B; Feliciano J; Georgiades C; Verde F; Illei P; Li QK; Gabrielson E; Brock MV; Isbell JM; Sauter JL; Taube J; Scharpf RB; Karchin R; Pardoll DM; Chaft JE; Hellmann MD; Brahmer JR; Velculescu VE
Cancer Res; 2019 Mar; 79(6):1214-1225. PubMed ID: 30541742
[TBL] [Abstract][Full Text] [Related]
8. Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC.
Hellmann MD; Nabet BY; Rizvi H; Chaudhuri AA; Wells DK; Dunphy MPS; Chabon JJ; Liu CL; Hui AB; Arbour KC; Luo J; Preeshagul IR; Moding EJ; Almanza D; Bonilla RF; Sauter JL; Choi H; Tenet M; Abu-Akeel M; Plodkowski AJ; Perez Johnston R; Yoo CH; Ko RB; Stehr H; Gojenola L; Wakelee HA; Padda SK; Neal JW; Chaft JE; Kris MG; Rudin CM; Merghoub T; Li BT; Alizadeh AA; Diehn M
Clin Cancer Res; 2020 Jun; 26(12):2849-2858. PubMed ID: 32046999
[TBL] [Abstract][Full Text] [Related]
9. Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC).
Ricciuti B; Jones G; Severgnini M; Alessi JV; Recondo G; Lawrence M; Forshew T; Lydon C; Nishino M; Cheng M; Awad M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771889
[TBL] [Abstract][Full Text] [Related]
10. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study.
Forschner A; Battke F; Hadaschik D; Schulze M; Weißgraeber S; Han CT; Kopp M; Frick M; Klumpp B; Tietze N; Amaral T; Martus P; Sinnberg T; Eigentler T; Keim U; Garbe C; Döcker D; Biskup S
J Immunother Cancer; 2019 Jul; 7(1):180. PubMed ID: 31300034
[TBL] [Abstract][Full Text] [Related]
11. Very early response of circulating tumour-derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non-small cell lung cancer.
Iijima Y; Hirotsu Y; Amemiya K; Ooka Y; Mochizuki H; Oyama T; Nakagomi T; Uchida Y; Kobayashi Y; Tsutsui T; Kakizaki Y; Goto T; Miyashita Y; Omata M
Eur J Cancer; 2017 Nov; 86():349-357. PubMed ID: 29078173
[TBL] [Abstract][Full Text] [Related]
12. Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors.
van der Leest P; Hiddinga B; Miedema A; Aguirre Azpurua ML; Rifaela N; Ter Elst A; Timens W; Groen HJM; van Kempen LC; Hiltermann TJN; Schuuring E
Mol Oncol; 2021 Nov; 15(11):2910-2922. PubMed ID: 34449963
[TBL] [Abstract][Full Text] [Related]
13. Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study.
Pécuchet N; Zonta E; Didelot A; Combe P; Thibault C; Gibault L; Lours C; Rozenholc Y; Taly V; Laurent-Puig P; Blons H; Fabre E
PLoS Med; 2016 Dec; 13(12):e1002199. PubMed ID: 28027313
[TBL] [Abstract][Full Text] [Related]
14. Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients.
Ashida A; Sakaizawa K; Uhara H; Okuyama R
Acta Derm Venereol; 2017 Nov; 97(10):1212-1218. PubMed ID: 28681063
[TBL] [Abstract][Full Text] [Related]
15. Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
Francaviglia I; Magliacane G; Lazzari C; Grassini G; Brunetto E; Dal Cin E; Girlando S; Medicina D; Smart CE; Bulotta A; Gregorc V; Pecciarini L; Doglioni C; Cangi MG
Lung Cancer; 2019 Aug; 134():225-232. PubMed ID: 31319985
[TBL] [Abstract][Full Text] [Related]
16. Personalized circulating tumor DNA detection to monitor immunotherapy efficacy and predict outcome in locally advanced or metastatic non-small cell lung cancer.
Cheng L; Gao G; Zhao C; Wang H; Yao C; Yu H; Yao J; Li F; Guo L; Jian Q; Chen X; Li X; Zhou C
Cancer Med; 2023 Jul; 12(13):14317-14326. PubMed ID: 37184093
[TBL] [Abstract][Full Text] [Related]
17. Monitoring immunotherapy outcomes with circulating tumor DNA.
Goldberg SB; Patel AA
Immunotherapy; 2018 Sep; 10(12):1023-1025. PubMed ID: 30185140
[No Abstract] [Full Text] [Related]
18. Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study).
Garlan F; Laurent-Puig P; Sefrioui D; Siauve N; Didelot A; Sarafan-Vasseur N; Michel P; Perkins G; Mulot C; Blons H; Taieb J; Di Fiore F; Taly V; Zaanan A
Clin Cancer Res; 2017 Sep; 23(18):5416-5425. PubMed ID: 28576867
[No Abstract] [Full Text] [Related]
19. Immune and Circulating Tumor DNA Profiling After Radiation Treatment for Oligometastatic Non-Small Cell Lung Cancer: Translational Correlatives from a Mature Randomized Phase II Trial.
Tang C; Lee WC; Reuben A; Chang L; Tran H; Little L; Gumbs C; Wargo J; Futreal A; Liao Z; Xia X; Yi X; Swisher SG; Heymach JV; Gomez D; Zhang J
Int J Radiat Oncol Biol Phys; 2020 Feb; 106(2):349-357. PubMed ID: 31678224
[TBL] [Abstract][Full Text] [Related]
20. Application of circulating tumor DNA for dynamic monitoring of advanced non-small cell lung cancer treatment response: An open-label, multicenter, prospective, observational study protocol.
Gao Z; Shang Y; Wang X; Ma Y; Yang F; Wang J; Chen K; Zhang Y
Thorac Cancer; 2019 May; 10(5):1310-1315. PubMed ID: 30980496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]